tretinoin and Arterial-Occlusive-Diseases

tretinoin has been researched along with Arterial-Occlusive-Diseases* in 4 studies

Reviews

1 review(s) available for tretinoin and Arterial-Occlusive-Diseases

ArticleYear
[Acute lower limb ischemia revealing acute leukemia. Case report and review of the literature].
    Journal des maladies vasculaires, 2010, Volume: 35, Issue:1

    Large vessel thrombosis is a very rare clinical presentation of acute leukemia which is usually revealed by hemorrhagic complications or thrombosis of small vessels. We present here the case of a patient with previously undiagnosed acute myeloid leukemia who was referred to our hospital with symptoms of acute ischemia of the left lower limb. Occlusion of the left popliteal artery due to a leucostasis was noted and successfully treated with emergency surgical thromboembolectomy and chemotherapy.

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cytarabine; Daunorubicin; Emergencies; Femoral Artery; Humans; Ischemia; Leg; Leukemia, Promyelocytic, Acute; Leukostasis; Male; Popliteal Artery; Remission Induction; Thrombectomy; Tretinoin

2010

Other Studies

3 other study(ies) available for tretinoin and Arterial-Occlusive-Diseases

ArticleYear
Acute arterial thrombosis in acute promyelocytic leukaemia.
    Clinical and laboratory haematology, 2003, Volume: 25, Issue:4

    Localized large vessel thrombosis in acute leukaemia is rare, haemorrhagic complications being more common.. We present a patient with acute promyelocytic leukaemia (APL) presenting with an acutely ischaemic lower limb. Large vessel thrombosis is a rare presentation of APL. We reviewed the literature on the coagulopathy of APL and discuss the pathology and current treatment options.. Disordered haemostasis is typical of acute promyelocytic leukaemia (FAB M3) and relates to the intrinsic properties of the blast cells as well as thrombocytopenia from bone marrow involvement. Expression of procoagulants, stimulation of cytokines and alterations in endothelial cell anticoagulant properties initiate a disseminated intravascular coagulation (DIC) resulting in the typical clinical and laboratory findings in APL. The promyelocytes are characterized by the balanced reciprocal translocation between chromosomes 15 and 17. All-trans-retinoic acid (ATRA) induces differentiation in these cells, revolutionizing the treatment of APL.. Unexpected limb ischaemia in a young, apparently healthy patient might be the presenting symptom of an underlying haematological disorder such as APL. A thorough haematological investigation should be performed prior to contemplating surgery. New treatment strategies based on knowledge of the molecular biology of APL has improved the prognosis of patients suffering from APL.

    Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cysteine Endopeptidases; Cytarabine; Daunorubicin; Female; Gangrene; Humans; Intermittent Claudication; Ischemia; Leg; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Popliteal Artery; Remission Induction; Smoking; Thioguanine; Thrombophilia; Thromboplastin; Thrombosis; Toes; Tretinoin

2003
Prevention of homocysteine thiolactone induced atherogenesis in rats.
    Research communications in molecular pathology and pharmacology, 2002, Volume: 111, Issue:5-6

    Thioretinamide was conjugated to coenzyme B12 to produce thioretinaco. Thioretinamide, thioretinaco, and coenzyme B12 were injected weekly into Rattus rattus that were also given atherogenic doses of homocysteine thiolactone. The presence or absence of lesions in aorta-intercostal artery junctions was examined. Control rats injected with homocysteine thiolactone (CON-Hcy) had 56.6 +/- 5.8% lesions when compared to 34.8 +/- 3.4% in control rats injected with saline (CON-Sal). Rats that received homocysteine thiolactone injection with thioretinamide (NHTR-Hcy), thioretinaco ((NHTR)2B12-Hcy), and coenzyme B12 (B12-Hcy) had 30.1 +/- 4.2%, 27.5 +/- 3.5%, and 22.8 +/- 3.0% lesions, respectively. These lesion rates were not different from those of rats receiving thioretinamide (NHTR-Sal), thioretinaco ((NHTR)2B12-Sal), and coenzyme B12 (B12-Sal) which were 31.3 +/- 1.8%, 29.8 +/- 3.9%, and 32.0 +/- 4.6%, respectively. In this study the percentage of intercostal artery lesions in rats receiving thioretinamide and homocysteine (NHTR-Hcy), coenzyme B12 and homocysteine (B12-Hcy), and thioretinaco and homocysteine ((NHTR)2/B12-Hcy) were significantly lower, 53.2%, 48.6%, and 40.3% respectively, compared to than that of the control group receiving homocysteine (CON-Hcy). Thioretinaco, thioretinamide, and coenzyme B12 provided protective effects against the atherogen homocysteine thiolactone. A new method for the synthesis of the N-substituted derivative of homocysteine thiolactone, thioretinamide, was also reported.

    Topics: Animals; Aorta, Thoracic; Arterial Occlusive Diseases; Arteries; Arteriosclerosis; Cobamides; Female; Food; Homocysteine; Magnetic Resonance Spectroscopy; Mass Spectrometry; Propylene Glycol; Rats; Tissue Fixation; Tretinoin; Vitamin B 12; Weight Gain

2002
Acute arterial occlusion as the presenting feature in acute promyelocytic leukaemia.
    British journal of haematology, 2001, Volume: 115, Issue:1

    Topics: Amputation, Surgical; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cytarabine; Daunorubicin; Female; Foot Diseases; Heparin; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Necrosis; Popliteal Artery; Thioguanine; Tretinoin

2001